Subscribe: LexisNexis® Mealey's™ Antidepressant Drugs Legal News
http://feeds.feedburner.com/AntidepressantDrugsLegalNews
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
beecham corp  corp glaxosmithkline  court  full story  full  judge  lexis  page full  page  paxil  smithkline beecham  story lexis  story 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: LexisNexis® Mealey's™ Antidepressant Drugs Legal News

LexisNexis® Mealey's™ Antidepressant Drugs Legal News



Headline Antidepressant Drugs Legal News from LexisNexis®



 



7th Circuit Says Post-2002 Effexor Warnings Were Properly Excluded
CHICAGO - Wyeth's victory in the nation's first federal Effexor suicide trial was upheld Feb. 12 by the Seventh Circuit U.S. Court of Appeals when it affirmed a district court judge's decision barring a widow from introducing evidence about Effexor's suicide warnings after her husband's death on the ground that the probative value of the post-2002 warnings was substantially outweighed by the danger of confusing the jury (Jacquelyn Giles v. Wyeth Inc., et al., No. 07-3149, 7th Cir.; 2009 U.S. App. LEXIS 2651; See January 2008, Page 15). Full story on lexis.com



Judge: Birth Defect Case Would Not Benefit From MDL Proceedings
ST. LOUIS - A woman's claims that her use of Celexa during her pregnancy caused her son's death nine months after his birth should be remanded to the court where it was originally filed, the federal judge presiding over the federal multidistrict litigation involving attempted suicide and suicide claims allegedly caused by use of Celexa and Lexapro ruled Feb. 5, after finding that the case would not benefit from the proceedings (In re: Celexa & Lexapro Products Liability Litigation, MDL No. 1736, Case No. 06-md-1736, Debra Drewry v. Forest Laboratories Inc., No. 06CV717, E.D. Mo.). Full story on lexis.com



Wyeth: Pfizer Deal Merits No Change In Preemption Case
WASHINGTON, D.C. - Wyeth on Feb. 4 told the U.S. Supreme Court about Pfizer Inc.'s plans to buy Wyeth but said that warrants no change in its corporate disclosure statement filed in the Wyeth v. Diana Levine drug preemption case pending before the court (Wyeth v. Diana Levine, No. 06-1249, U.S. Sup.; See November 2008, Page 8). Full story on lexis.com



Stay In Paxil Preemption Appeal Extended Until May
SAN FRANCISCO - The stay of proceedings in a couple's appeal of a federal judge's finding that their failure-to-warn claims against the maker of Paxil are preempted by U.S. Food and Drug Administration regulations was extended until May 11, according to an order docketed Feb. 19 in the Ninth Circuit U.S. Court of Appeals (Terri S. O'Neal v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. No. 08-16182, 9th Cir.; See January 2009, Page 9). Full story on lexis.com



Magistrate Judge Compels GSK To Produce Paxil Revenue, Profit Data
HAMMOND, Ind. - A federal magistrate judge on Feb. 3 ordered SmithKline Beecham Corp., d/b/a GlaxoSmithKline (GSK), to produce information related to the profit and revenue it received from pediatric sales of Paxil in Indiana and the United States from 2000 to 2004 to a family who claims that the antidepressant caused a 14-year-old boy to commit suicide in 2001, after finding that the information is relevant to their claim for punitive damages (Cheryl Cunningham, et al. v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-CV-174, N.D. Ind.; 2009 U.S. Dist. LEXIS 7833; See August 2008, Page 16). Full story on lexis.com



MDL Plaintiffs Seek Access To Clinical Trial Documents
ST. LOUIS - Plaintiffs in the Celexa and Lexapro multidistrict litigation say in a Feb. 13 motion to compel that they should be given access to hard copy documents in the antidepressants' clinical trial files because the information is "the most pure and objective form" of knowledge available (In re: Celexa/Lexapro Products Liability Litigation, MDL No. 1736, Case No. 06-md-1736, E.D. Mo.). Full story on lexis.com



Wyeth Seeks To Supplement Plaintiff's Deposition Based On New Evidence
PITTSBURGH - A plaintiff's failure to respond to Wyeth's requests for additional information regarding his own attempted suicide considering he alleges in his lawsuit that his brother's use of Effexor caused his suicide warrants the entry of a court order compelling the plaintiff to appear for a supplemental deposition, the manufacturer argues in a Jan. 29 motion to compel (Dale Aaron v. Wyeth, No. 07-927, W.D. Pa.; See November 2007, Page 16). Full story on lexis.com



Woman Says Good Faith, Facts Of Case Warrant Denial Of Costs
ROME, Ga. - A woman whose Paxil suicide lawsuit was found to be barred by the learned intermediary doctrine says in a Feb. 16 brief that a federal judge has discretion to relieve her from paying costs because she litigated her claims against the maker of the antidepressant in good faith and because the facts of the case militate against the imposition of costs (Donna L. Dietz v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-cv-77-RLV, N.D. Ga.; See January 2009, Page 10). Full story on lexis.com



Parties Jointly Move To Dismiss Paxil Suicide Attempt Case
BRATTLEBORO, Vt. - The manufacturer of Paxil and a woman who claims that her use of the antidepressant caused her to attempt suicide when she was 16 years old jointly moved Feb. 20 to dismiss with prejudice her lawsuit (Jennifer Elwell v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-CV-191, D. Vt.; See April 2007, Page 17). Full story on lexis.com



Researchers Say SSRIs Reduce Suicide Risk In Adults
OTTAWA, Ontario - The authors of a recently published study in the Canadian Medial Association Journal concluded that the use of a family of antidepressants known as selective serotonin reuptake inhibitors (SSRIs) by adult patients may reduce the risk of suicide. Full story on lexis.com



FDA Approves Updated Warning For SSRI, SNRI Makers
SILVER SPRING, Md. - The U.S. Food and Drug Administration on Jan. 30 informed manufacturers of numerous selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs) that it has approved updated warning language regarding the risk of neuroleptic malignant syndrome (NMS) that they companies need to add to their products' labels. Full story on lexis.com



Judge Asks If Birth Defect Case Should Stay In MDL
ST. LOUIS - The federal judge presiding over the Celexa and Lexapro multidistrict litigation asked the parties on Jan. 22 to submit memoranda explaining why a birth defect case and a death case should remain in the proceedings (In re: Celexa & Lexapro Products Liability Litigation, MDL No. 1736, E.D. Mo.; 2009 U.S. Dist. LEXIS 4204; See August 2008, Page 6). Full story on lexis.com



Judge Refers Discovery Dispute To Magistrate Judge
TULSA, Okla. - SmithKline Beecham Corp. d/b/a GlaxoSmithKline's (GSK) request to modify a special judge's report and recommendation concerning its privilege assertions over documents requested in a Paxil birth defect case was referred to a magistrate judge by a federal judge on Jan. 12 (Jennifer Hayes and Justin Hayes v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-CV-0682, N.D. Okla.; See December 2008, Page 13). Full story on lexis.com



Oral Arguments On Paxil Limitations Ruling Scheduled For March 10
DENVER - The 10th Circuit U.S. Court of Appeals will hear oral arguments on March 10 over whether a federal judge in Kansas properly found that a woman's claims that SmithKline Beecham Corp. d/b/a GlaxoSmithKline's (GSK) fraudulent concealment of its knowledge concerning the risk between Paxil and an increased risk of suicide in adolescent patients were insufficient to toll the statute of limitations, according to a scheduling order issued to counsel on Jan. 13 (Pamela Blain, et al. v. SmithKline Beecham Corp., Nos. 08-3131, 08-3140, 10th Cir.; See November 2008, Page 11). Full story on lexis.com



Generic Paxil Case Remanded After Plaintiffs Amend Complaint
LAFAYETTE, La. - A federal magistrate judge on Dec. 16 remanded a family's wrongful death suit against a manufacturer of generic Paxil after they amended their complaint to name as a defendant the physician who prescribed and increased the dosage of the antidepressant to the decedent without first meeting him and monitoring his behavior when first using the drug (Mary Lee Delahoussaye, et al. v. Apotex Inc., et al., No. 07-1325, W.D. La.; See December 2008, Page 8). Full story on lexis.com



California Supreme Court Won't Review Ruling Holding Brand-Name Drug Maker Liable
SAN FRANCISCO - The California Supreme Court on Jan. 21 let stand an appeals court ruling that the brand-name manufacturer of a drug can be liable for a failure-to-warn claim involving the generic version of the drug (Elizabeth Ann Conte v. Wyeth, et al., No. S169116, Calif. Sup.). Full story on lexis.com



Paxil Preemption Appeal Stay Extended To March 10
SAN FRANCISCO - The stay of a couple's appeal of a federal judge's rulings finding their failure-to-warn claims against Paxil manufacturer SmithKline Beecham d/b/a GlaxoSmithKline (GSK) preempted by Food and Drug Administration regulations was extended to March 10, according to a Jan. 9 order filed in the Ninth Circuit U.S. Court of Appeals (Terri S. O'Neal, et al. v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 08-16182, 9th Cir.; See October 2008, Page 5). Full story on lexis.com



Appellate Panel Finds Evidence Does Not Support Involuntary Intoxication Claim
SAN FRANCISCO - A California appeals panel on Jan. 2 affirmed the conviction of a man found guilty of murdering his wife, finding that there was insufficient evidence to warrant reversal of the trial court's decision not to instruct the jury on his argument that he was unconscious by involuntary intoxication brought about by his use of Paxil at the time of the crime (People v. Simon Faeed Ranteesi, No. A115311, Calif. App., 1st Dist., Div. 2; 2009 Cal. App. LEXIS 20). Full story on lexis.com



Widow Asks Judge To Limit, Defer Costs From Paxil Suit
ROME, Ga. - A widow whose wrongful death suit against the maker of Paxil was recently dismissed asked a federal judge on Jan. 22 to limit the amount of costs the company is awarded and requested that any such payments be deferred until the completion of her appeal (Donna Dietz v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-CV-0077-RLV, N.D. Ga.; See December 2008, Page 10). Full story on lexis.com



Canadian Drug Company Serves Notice Of Arbitration On United States Under NAFTA
WASHINGTON, D.C. - Apotex Inc., a Canadian pharmaceutical company, served a notice of arbitration on the United States on Dec. 10, alleging that the United States violated Chapter 11 of the North American Free Trade Agreement (NAFTA) through federal court rulings that prevented the company from obtaining a declaratory judgment of patent noninfringement or invalidity and, therefore, from promptly bringing its generic product to the market (Apotex Inc. v. The Government of the United States of America, UNCITRAL). Full story on lexis.com



Study: Zoloft, Lexapro Best For Moderate To Severe Depression
LONDON - Pfizer Inc.'s Zoloft and Forest Laboratories Inc.'s Lexapro, also known as Cipralex, should be a psychiatrist's first choice when deciding what drug to prescribe to a patient suffering from moderate to severe depression, according to the authors of a new study published in a recent online issue of Lancet who found that the drugs performed marginally better than 10 other antidepressants reviewed. Full story on lexis.com



Pfizer Plans To Acquire Wyeth For $68 Billion
NEW YORK - Pharmaceutical giant Pfizer Inc. announced Jan. 26 that it plans to acquire rival drug company Wyeth for $68 billion, resulting in what the company calls a "combined company that will create one of the most diversified companies in the global health care industry." Full story on lexis.com



GSK Claims Ruling Excluding Expert's Opinion Was Correct
DENVER - A district court's ruling that a plaintiff's expert's opinions as to whether Paxil can cause suicidal behavior and that a man's use of the antidepressant caused him to take his own life in 2003 was not erroneous, the drug maker says in a Dec. 1 appellate brief, because the expert believed that such an association existed before the drug was approved by the Food and Drug Administration. (Debra Vanderwerf v. SmithKline Beecham Corp., No. 08-3218, 10th Cir.; See November 2008, Page 5). Full story on lexis.com



State Justice Finds Plaintiffs' Experts Qualified; Only 1 Can Testify
WORCESTER, Mass. - Only one expert can provide testimony in support of a man's claims that a physician was medically negligent when prescribing Wellbutrin to his wife before her suicide, a Massachusetts Superior Court justice ruled after finding that though both experts were qualified to proffer general and specific causation opinions, only one employed a proper methodology to support his opinions. (Allan Routhier v. Timothy G. Keenan, M.D., No. 04-1359, Mass. Super., 2008 Mass. Super. LEXIS 372). Full story on lexis.com



Companies Say Preemption Ruling Is Not Worthy Of Certification
WASHINGTON, D.C. - A Third Circuit U.S. Court of Appeals ruling that plaintiffs' claims against the makers of Paxil and its generic equivalent and Zoloft are preempted by Food and Drug Administration regulations should not be reviewed by the U.S. Supreme Court because the ruling is not erroneous, the makers of the antidepressants say in briefs filed Dec. 3 (Joseph Colacicco, et al. v. Apotex Inc, et al., No. 08-437, U.S. Sup.; See October 2008, Page 4.). Full story on lexis.com



Generic Paxil Maker Again Raises Preemption Defense
LAFAYETTE, La. - A generic Paxil maker is seeking summary judgment based on the preemption defense in a wrongful death case, slightly more than a year after a federal judge denied its motion to dismiss the case on the ground that the manufacturer had both "the power and the duty" to add a stronger suicide warning to the antidepressant's label (Mary Lee Delahoussaye, et al. v. Apotex Inc., et al., No. 07-1325, W.D. La.; See November 2007, Page 4). Full story on lexis.com



Plaintiffs Fail To Plead Exception To Michigan Law, Appeals Court Rules
NEW YORK - A New York appeals court on Nov. 20 affirmed that Michigan state law applies to the Lipitor injury claims of three plaintiffs and that they had not provided a foundation for their argument that their claims fell under the fraud exception to Michigan's drug shield law (Michael Devore, et al. v. Pfizer Inc., Nos. 109838/06, 109845/06, 109847/06, N.Y. Sup., App. Div., 1st Dept.; 2008 N.Y. App. Div. 8707). Full story on lexis.com



GSK Awarded Summary Judgment In Paxil Suicide Case
ROME, Ga. - The manufacturer of Paxil's assertion that the learned intermediary doctrine bars a widow's claims that it is liable for her husband's April 2002 suicide was upheld by a federal judge on Dec. 9, after finding that the 11th Circuit U.S. Court of Appeals recently held that a plaintiff cannot prove proximate causation if the prescribing physician testifies that his or her decision to prescribe a drug would not have been altered by a stronger warning. (Donna Dietz v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-CV-0077-RLV, N.D. Ga.; See April 2007, Page 22). Full story on lexis.com



Man Says Lilly's Summary Judgment Motion Is A Waste Of Time
ATLANTA - A motion for summary judgment filed by the maker of Prozac in a case involving claims that the antidepressant caused a man to experience a manic episode resulting in his incarceration is a waste of time, the plaintiff says in a Nov. 26 brief, explaining that the two arguments raised in the motion have already been rejected by a Georgia state court judge (Tom Watkins v. Eli Lilly & Company, No. 08-CV-1665 JEC, N.D. Ga.; See November 2008, Page 6). Full story on lexis.com



Plaintiffs: Lilly Has 'Unbelievable Chutzpah' To Seek Review
ALBUQUERQUE, N.M. - The maker of Prozac should be estopped from seeking review of a judge's rulings denying its motions for summary judgment based on the learned intermediary doctrine and federal preemption and of his decision finding plaintiffs' expert's testimony admissible because it waited until after the judge issued the orders to ask him to disqualify himself, plaintiffs say in a Nov. 20 opposition brief (Mark Gilbert Rimbert v. Eli Lilly & Co., No. 06-cv-874, D. N.M.; See October 2008, Page 10). Full story on lexis.com



Couple's Request To Name Parent Company In Lawsuit Denied
TULSA, Okla. - A couple's attempt to add GlaxoSmithKline plc (GSK plc) and GlaxoSmithKline Research and Development (GSK R&D) as defendants in their Paxil birth defect lawsuit was rejected by a federal judge, who concluded that they could not pursue claims against the companies because they were not involved in the marketing and manufacture of the antidepressant (Jennifer Hayes and Justin Hayes v. SmithKline Beecham Corp., d/b/a GlaxoSmithKline, No. 07-CV-0682, N.D. Okla.; 2008 U.S. Dist. LEXIS 94697). Full story on lexis.com



Lilly Employee Should Be Ordered To Appear Live At Trial, Couple Says
SIOUX FALLS, S.D. - An Eli Lilly & Co. employee who studied and wrote articles about the association between Prozac and suicidal behavior should be ordered to appear live at a trial involving claims brought by a couple who claim that their son's use of Cymbalta caused him to commit suicide, the parents say, because his knowledge is germane to their underlying allegations and because the court has the power to compel his presence (Paul and Cynthia Schilf v. Eli Lilly & Co., et al., No. 07CV04015-LLP, D. S.D.; See October 2008, Page 8). Full story on lexis.com